ReviewFrontiers in cell and developmental biology2026
LncRNA SNHG3: a potential biomarker for human diseases.
Review in Frontiers in cell and developmental biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With advancements in high-throughput sequencing and molecular biology technologies, the emerging significance of long non-coding RNAs (lncRNAs) in pathological conditions has been progressively unveiled. SNHG3, a member of the small nuclear RNA host gene (SNHG) family, is localized in both the nucleus and cytoplasm, and plays a pivotal role in multiple aspects of RNA metabolism, including transcription, splicing, translation and stability. Accumulating evidence indicates that SNHG3 is implicated in various human diseases, with a predominant focus on its oncogenic functions in different malignancies. Mechanistically, SNHG3 exerts its pathological functions by acting as a miRNA sponge, co-transcription factor or repressor, and stabilizer for oncogenic transcripts. Recent studies have further uncovered the essential role of SNHG3 in neurological disorders, such as brain injury, spinal cord injury, and drug-induced nerve injury. In this review, we comprehensively summarize the involvement of SNHG3 in various human diseases, and highlight its dual potential as a diagnostic and prognostic biomarker. Furthermore, we elucidate the regulatory mechanisms by which SNHG3 influences multiple RNA metabolism processes in related pathological processes, and propose its potential role in alternative splicing and the formation of cytoplasmic or nucleic ribonucleoprotein (RNP) granules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.